SCHEMBL3075017

SCHEMBL3075017

COCCCOc1cc(CCl)cc(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
AHR P35869 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2D6 P10635 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP19A1 P11511 1/20 0.36
CNR1 P21554 4/20 0.35
CNR2 P34972 4/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KCNA3 P22001 1/20 0.35
CALM1 P0DP23 2/20 0.34
AKR1B1 P15121 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90334 0.86 CNR1 (0.40) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL2808413 0.85 MEN1 (0.36) ALDH1A1CYP1A2CYP2C19CYP2D6MAPK1
SCHEMBL88959 0.84 ALDH1A1 (0.44) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL1279836 0.82 ALDH1A1 (0.58) ALDH1A1CYP1A2CYP2C19CYP2D6MAPK1
SCHEMBL89284 0.82 ALDH1A1 (0.39) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL8264192 0.82 MAOB (0.41) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL8237574 0.82 ALDH1A1 (0.39) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL11261073 0.80 ALDH1A1 (0.55) ALDH1A1CYP1A2CYP2C19CYP2D6MAPK1
SCHEMBL88961 0.80 ALDH1A1 (0.48) ALDH1A1AHRCYP1A2CYP2C19CYP2D6
SCHEMBL4602701 0.79 ALDH1A1 (0.44) ALDH1A1AHRCYP1A2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 ALDH1A1 142/4885AHR 2355/4885CYP1A2 51/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 ALDH1A1 142/4885AHR 2355/4885CYP1A2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.